FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Dysfunction topics
Dysfunction
Hypertension
Vascular Disease
Spinal Cord
Endothelial
Steoporosis
Endothelial Dysfunction
Nephropathy
Osteoporosis
Congestive Heart Failure
Theophylline
Sexual Dysfunction
Myocardial Infarction
Infarction
Cardiovascular Disease

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Dysfunction patents



      
           
This page is updated frequently with new Dysfunction-related patent applications. Subscribe to the Dysfunction RSS feed to automatically get the update: related Dysfunction RSS feeds. RSS updates for this page: Dysfunction RSS RSS


Date/App# patent app List of recent Dysfunction-related patents
07/24/14
20140206707
 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same patent thumbnailnew patent 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
07/24/14
20140206698
 Methods of diagnosing diastolic dysfunction patent thumbnailnew patent Methods of diagnosing diastolic dysfunction
Diagnostic methods relating to a cardiac ventricular dysfunction are provided. In some embodiments, the diagnostic method is a method of diagnosing diastolic dysfunction in the absence of systolic dysfunction in a subject.
07/24/14
20140206676
 Substituted 4-(1h-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of machr m1 receptors patent thumbnailnew patent Substituted 4-(1h-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of machr m1 receptors
In one aspect, the invention relates to substituted 4-(1h-pyrazol-4-yl)benzyl analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
07/24/14
20140206641
 Remedy patent thumbnailnew patent Remedy
It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis.
07/24/14
20140206612
 Oral insulin therapies and protocol patent thumbnailnew patent Oral insulin therapies and protocol
Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration.
07/24/14
20140205658
 Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction patent thumbnailnew patent Compositions and methods for treating or preventing radiation- or chemotherapy-induced pulmonary dysfunction
Compositions comprising one or more cytokines and methods for their use in inhibiting and/or alleviating effects of radiation therapy and/or chemotherapy and/or acute radiation syndrome in a subject in need thereof are provided.. .
07/24/14
20140205565
 Compositions and methods for treating organ dysfunction patent thumbnailnew patent Compositions and methods for treating organ dysfunction
A method of retarding cellular senescence comprising (i) providing an extracellular matrix (ecm) composition comprising ecm from an adolescent tissue source, the ecm comprising an exogenously added cytokine, and (ii) administering ecm composition to an organ with cells exhibiting cellular senescence, wherein, the cytokine interacts with at least one molecule in the ecm composition and modulates ros production of the cells, whereby, the cellular senescence is abated.. .
07/17/14
20140200646
 Compressible device patent thumbnailCompressible device
An electro-stimulation device for the treatment of anterior and posterior pelvic floor muscle dysfunction is reversibly compressible and is fully self-contained. The device requires no external power sources or control and may be inserted into the vagina or anus through the use of an applicator.
07/17/14
20140200403
 Systems and methods for treating dysfunctions in the intestines and rectum that adapt to the anatomic form and structure of different individuals patent thumbnailSystems and methods for treating dysfunctions in the intestines and rectum that adapt to the anatomic form and structure of different individuals
A family of barrel structures is provided in a kit. Each barrel structure is differently sized and configured for advancement into anal canals of different anatomic morphologies.
07/17/14
20140200387
 Method and system for treatment of mobility dysfunction patent thumbnailMethod and system for treatment of mobility dysfunction
Effective systems and methods for improving neural communication impairment of a vertebrate being and affecting motor activity of a peripheral body part including a first signal providing component configured to provide pulsed peripheral stimulation signals at the peripheral body part, a second signal providing component configured to provide a pulsed motor cortex stimulation signal to a motor cortex area, a substantially dc signal providing component configured to provide direct current spinal stimulation signal at a neural spinal junction and a controller component configured to control timing of the pulsed peripheral stimulation signals and the pulsed motor cortex stimulation signal.. .
07/17/14
20140200219
Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
The present methods and compositions are of use for treatment of conditions involving fibrosis, such as peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a pde-4 inhibitor, a pde-5 inhibitor, a compound that elevates cgmp and/or pkg, a stimulator of guanylyl cyclase and/or pkg, a combination of a compound that elevates cgmp, pkg or no with an antioxidant that decreases ros, or a compound that increases mmp activity..
07/17/14
20140200208
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
The present invention relates to novel triazolo[4,3-a]pyridine derivatives of formula (i) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mglur2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mglur2 subtype of metabotropic receptors is involved.
07/17/14
20140200178
Method of detection of clinically significant post-prandial hyperglycemia in normoglycemic patients
This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (ahb) in a single fasting baseline biological sample of the patient; (b) comparing the level of ahb in the single fasting baseline biological sample to a reference ahb level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b).
07/17/14
20140200177
Method of detection of occult pancreatic beta cell dysfunction in normoglycemic patients
This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (ahb) in a single fasting baseline biological sample of the patient; (b) comparing the level of ahb in the single fasting baseline biological sample to a reference ahb level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b).
07/17/14
20140199692
Translational dysfunction based therapeutics
Provided are methods and compositions for inhibiting eukaryotic translation initiation factor eif4e. Such methods and compositions may be used alone or in conjunction with other therapies, such as gene therapies, for inhibiting cell proliferation and/or treating cancer..
07/17/14
20140199315
Sp35 antibodies and uses thereof
Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (negative regulator). Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction.
07/10/14
20140194910
Vessel shaping devices and methods
Disclosed is a medical device for shaping a vessel accommodated therein in a predetermined form, wherein said vessel includes a vein and an artery which are connected at a artifactual vascular junction thereof. The device includes an external vascular support (100) having at least one vascular support wall for accommodating an exterior vessel wall of a vessel therein when implanted.
07/10/14
20140194808
Methods and systems for use of photolyzable nitric oxide donors
The present disclosure relates to methods and systems for use of photolyzable nitric oxide donors for the treatment of sexual dysfunction.. .
07/10/14
20140194754
Method and device for detecting and assessing reactive hyperemia using segmental plethysmography
A method for measuring reactive hyperemia in a subject is disclosed. The method includes performing a first segmental cuff plethysmography to generate a baseline arterial compliance curve and/or a baseline pressure-area (p-a) curve, performing a second segmental cuff plethysmography to generate a hyperemic arterial compliance curve and/or a hyperemic p-a curve, and calculating an area between the baseline and the hyperemic curves.
07/10/14
20140194471
Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine m1 receptors
In one aspect, the invention relates to substituted 1-benzylindolin-2-one analog compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
07/10/14
20140194353
Compositions and methods for the treatment of nervous disorders associated with diabetes
Compositions and methods for treating neural dysfunction. A exemplary method comprises administering to a subject having a neuropathy, e.g., a cognitive dysfunction or alzheimer's, a therapeutically effective amount of an insulin or insulin analog, wherein the insulin or insulin analog crosses the bbb and/or a compound that increases srebp-2 expression or activity in the cns of the subject..
07/03/14
20140188191
Implantable neurostimulator for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration
A system for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration is provided. The system includes a patient-operable external controller to transmit a plurality of unique signals.
07/03/14
20140187608
Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
The present invention relates to methods and compositions for enhancing neuronal connectivity. It is based, at least in part, on the discovery of a protein, termed “mirta22,” that inhibits the formation of structures which create connections between neurons.
07/03/14
20140187605
Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg)
The invention relates to the field of endothelial barrier dysfunction, particular, the invention relates to new methods for the treatment of endothelial barrier dysfunction, such as inflammatory edema by inhibiting abl-related gene (arg).. .
07/03/14
20140187600
Use of metabotropic glutamate receptors
The invention concerns the use an mglur modulator, e.g. An mglur5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction..
07/03/14
20140187509
Use of s-adenosylmethionine, vitamin e, and vitamin c for the prevention and treatment of cardiovascular dysfunction
The present invention provides a method of preventing or treating cardiovascular dysfunction by administering a therapeutically effective amount of (a) one or more of (i) s-adenosylmethionine or a derivative or pharmaceutically acceptable salt thereof and (ii) n-acetylcysteine or a derivative or pharmaceutically acceptable salt thereof; (b) vitamin e or a derivative or pharmaceutically acceptable salt thereof; and (c) vitamin c or a derivative or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.. .
07/03/14
20140187444
Methods and compositions for detecting and modulating o-glycosylation
The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for identifying therapeutic compounds to treat glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction.
07/03/14
20140185001
Eyewear with lens retention feature and method of manufacture
Eyewear includes a set of lenses, a frame, and a pair of arms. A primary attachment feature facilitates attachment of the arms to the frames.
06/26/14
20140179726
Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. A human) to physiological processes within the host.
06/26/14
20140179662
Pharmaceutically active disubstituted triazine derivatives
The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase..
06/26/14
20140179597
Method for the treatment and prevention of alzheimer's disease and central nervous system dysfunction
Intranasal insulin is beneficial for the treatment of alzheimer's disease and other neurologic disorders. But commercial insulin preparations use metacresol, phenol, and other preservatives for chemical stabilization.
06/26/14
20140178357
Stabilized liquid and lyophilized adamts13 formulations
The present invention relates to formulations of adamts13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of adamts13 that are suitable for pharmaceutical administration.
06/26/14
20140177891
Separate inner and outer hair cell loss compensation
A method and device for compensating sensorineural hearing loss in a manner that allows dysfunction of the inner and outer hair cells to be separately compensated is described. The disclosed techniques involve providing separately adjustable compression pathways for the received sound..
06/19/14
20140171621
Galectin-immunoglobulin chimeric molecules
Described are galectin-1/ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.. .
06/19/14
20140171477
Derivatives of celeboxib, use thereof and preparation thereof
Derivatives of celecoxib that lack cyclooxygenase inhibitory activity but have improved pde5 inhibitory activity are provided along with pharmaceutical compositions containing them for the treatment or prevention of cancer. Such compounds are expected to have reduced toxicity compared with celecoxib and other cyclooxygenase inhibitors, and greater efficacy compared with conventional pde5 inhibitors.
06/19/14
20140171442
Alicyclic[c] benzopyrone derivatives and uses thereof
Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula i or their salts.
06/19/14
20140171387
Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
Since a compound represented by formula (i) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc.
06/12/14
20140163416
In vivo device and method for researching gi tract processes, microbes, and variables associated with illnesses and diseases
An orally ingested capsule has capabilities of sampling gut substances and microbes before, during and after delivery of system perturbation substances, to the gut at any point or time. Sensors are provided to simultaneously measure, monitor, record, and transmit data in real time obtained within the exact vicinity of substance deployment and microbial assisted digestive processes occur.
06/12/14
20140163314
Apparatus, system and operation method for the treatment of female sexual dysfunction
There is disclosed an apparatus for treating a sexual dysfunctional female patient, comprising an implanted stimulation device adapted to stimulate at least a part of the sexually responsive tissue of the vulva or the wall of the vagina of the patient by movement of said stimulation device and contact between said stimulation device and the sexually responsive tissue or the wall of the vagina. A system and an operation method for the treatment of female sexual dysfunction are also disclosed..
06/12/14
20140163065
Preparation and therapeutic applications of (2s, 3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (cns).. .
06/12/14
20140163062
Remedy for psychoneurotic diseases
A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.. .
06/12/14
20140163021
Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
Candidate compounds for use in neuro-protection and repair in neurological disorders involving tau dysfunction (including alzheimer's disease) are identified from a direct interaction between proteins fkbp52 and tau. The method for screening a drug for the prevention and treatment of neurological disorders involving tau dysfunction includes determining the ability of a candidate compound, to modulate binding between a tau polypeptide and a fkbp52 polypeptide, and selecting positively the candidate compound that modulates binding..
06/12/14
20140163017
Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
In one aspect, the invention relates to substituted (e)-n′-(1-phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including lsd1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the lsd1. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
06/12/14
20140162947
Kruppel-like factor 10 (klf10) as a biomarker of endothelial progenitor cell dysfunction
The use of kruppel-like factor (klf10) as a diagnostic and prognostic tool for peripheral artery disease and other disease conditions associated with reduced angiogenesis or endothelial progenitor cell dysfunction such as diabetes and stent thrombosis.. .
06/05/14
20140155784
Signal processing method and apparatus
The invention provides signal processing algorithms and apparatus for detecting bradykinesia, tremor, or other symptoms of neurological dysfunction in subjects, using three-dimensional sensors to tract finger and hand position. The invention provides cartesian genetic programming networks and particular function blocks for such networks to enable identification of subjects exhibiting such symptoms..
06/05/14
20140155691
Method of treating erectile dysfunction
A surgical method of treating erectile dysfunction includes implanting a penile prosthetic in a patient. The penile prosthetic includes an inflatable portion implantable into a penis that is attachable to a liquid reservoir, a pump, and a deflation assembly.
06/05/14
20140155393
1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
Wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mglur2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mglur2 subtype of metabotropic receptors is involved.
06/05/14
20140155339
Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants.
05/29/14
20140148871
Transcutaneous stimulation method and system
A method of treating a waste evacuation dysfunction comprising administering transcutaneous electrical stimulation (tes) to at least one lower pelvic and/or sacral region for a specific treatment regimens. Also disclosed is a system for configuring a stimulation device to deliver transcutaneous electrical stimulation (tes) the system comprising: a computing device storing or having access to a plurality or tes settings and comprising a user interface to enable authorised selection of at least on of the tes settings for provision of tes by the stimulation device according to the at least one selected tes setting and the stimulation device communicatively coupled to the computing device to receive and store the selected at least one tes setting the stimulation device being of a size to be readily carried on a body and configured to selectively provide current to external electrode according to the one tes setting..
05/29/14
20140148642
Magic genie developer
Apparatus and formulations for correcting and curing erectile dysfunction in men to create a natural erection without the use of primitive devices. The formulations will correct and cure erectile dysfunction along with the vacuum apparatus to aid the correction and cure, but also enhance the size of the penis after clearing out the plaque build-up and improve circulation to the male organ, by the use of the elongated cylinder to insert the penis into the plastic portal with the pulsating action with the other end closed, except for the intake vacuum pressure to help the formulations process to stimulate the penis and also the cleaning of arteries and vein build-up of plaque where the problem originally started to prevent the natural erection without any or poor blood circulation, which was the initial blockage in the arteries and veins in the corpus cavernosum and corpus sponglosum chambers the now formulations of #501 and #503 will work to clear up the circulation problems for ever and #502 will enhance the overall length and girth greater then prior erections..
05/29/14
20140148472
Gpr17-modulating compounds, diagnostic and therapeutic uses thereof
Disclosed are compounds able to modulate the activity of the gpr17 receptor in a highly specific way, which are useful in the treatment and diagnosis of diseases or dysfunctions involving the activation of said receptor. In particular, the compounds according to the invention can be used for neuroprotective and/or reparatory purposes, in cerebral, cardiac and renal ischaemia, in cerebral trauma, in chronic neurodegenerative diseases such as amyotrophic lateral sclerosis (als), and in demyelinating diseases such as multiple sclerosis..
05/29/14
20140148465
Compositions and methods to improve treatment of medical conditions using d-cycloserine
The invention describes methods and compositions for alleviating medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical compound that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction, wherein d-cycloserine is the pharmaceutical compound that enhances learning.
05/29/14
20140148437
Novel compounds as diacylglycerol acyltransferase inhibitors
This invention relates to novel compounds which are inhibitors of acyl coenzyme a: diacylglycerol acyltransferase 1 (dgat-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination with weight management therapies or other triglyceride lowering therapy for the prevention or treatment of diseases related to dgat-1 dysfunction or where modulation of dgat-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, genetic (type 1, type 5 hyperlipidemia) and acquired forms of hypertriglyceridemia or hyperlipoproteinemia-related disorders, caused by but not limited to lipodystrophy, hypothyroidism, medications (beta blockers, thiazides, estrogen, glucocorticoids, transplant) and other factors (pregnancy, alcohol intake), hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, cardiovascular outcomes, angina, excess hair growth (including syndromes associated with hirsutism), nephrotic syndrome, fibrosis such as myocardial, renal and liver fibrosis, hepatitis c virus infection and acne or other skin disorders.. .
05/29/14
20140148413
Compositions and methods for preventing and treating organ injury and/or dysfunction
The present embodiments relate to compositions and methods for treating the inflammatory response in a tissue or organ, such as the liver, by contacting the tissue with a tissue-specific gap junction inhibitor; and compositions and methods of reducing the toxicity of an agent by administering a gap junction inhibitor either simultaneously or sequentially with exposure to the agent. For example, inhibition of the liver-specific gap junction connexin 32 by 2 aminoethyoxydiphenyl-borate, effectively treats and/or prevents hepatotoxicity..
05/29/14
20140148385
Composition for preventing or treating erectile dysfunction comprising angiopoietin-4 protein
Provided is a composition for preventing or treating erectile dysfunction including angiopoietin-4 protein as an active ingredient. Angiopoietin-4 protein increases an endothelial cell-specific protein level to induce regeneration of penile vascular endothelial cells, thereby increasing intracavernous pressure.


Popular terms: [SEARCH]

Dysfunction topics: Dysfunction, Hypertension, Vascular Disease, Spinal Cord, Endothelial, Steoporosis, Endothelial Dysfunction, Nephropathy, Osteoporosis, Congestive Heart Failure, Theophylline, Sexual Dysfunction, Myocardial Infarction, Infarction, Cardiovascular Disease

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Dysfunction for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dysfunction with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2241

3551

0 - 1 - 72